Ladenburg Thalmann set a $57.00 target price on CoLucid Pharmaceuticals Inc. (NASDAQ:CLCD) in a research note released on Monday morning. The brokerage currently has a a buy rating on the biopharmaceutical company’s stock.

Other research analysts have also recently issued research reports about the company. Piper Jaffray Cos. reiterated a buy rating and issued a $36.00 price objective on shares of CoLucid Pharmaceuticals in a research report on Thursday, September 15th. Stifel Nicolaus increased their price objective on CoLucid Pharmaceuticals from $27.00 to $30.00 and gave the stock a buy rating in a research report on Monday. Finally, Zacks Investment Research upgraded CoLucid Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, May 31st. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. The stock has an average rating of Buy and a consensus price target of $30.45.

CoLucid Pharmaceuticals (NASDAQ:CLCD) opened at 31.06 on Monday. The firm’s market cap is $476.27 million. CoLucid Pharmaceuticals has a 12 month low of $3.57 and a 12 month high of $35.48. The stock’s 50 day moving average is $15.26 and its 200 day moving average is $9.18.

CoLucid Pharmaceuticals (NASDAQ:CLCD) last released its quarterly earnings data on Wednesday, August 10th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.84) by $0.22. On average, equities analysts forecast that CoLucid Pharmaceuticals will post ($3.91) earnings per share for the current year.

In related news, major shareholder Domain Partners Vi, L.P. sold 153,028 shares of CoLucid Pharmaceuticals stock in a transaction dated Wednesday, August 3rd. The stock was sold at an average price of $8.45, for a total transaction of $1,293,086.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder A/S Novo acquired 100,000 shares of the company’s stock in a transaction that occurred on Friday, September 9th. The shares were bought at an average price of $20.00 per share, with a total value of $2,000,000.00. Following the transaction, the insider now owns 3,156,563 shares in the company, valued at approximately $63,131,260. The disclosure for this purchase can be found here. 13.70% of the stock is owned by insiders.

Hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in CoLucid Pharmaceuticals by 1.2% in the second quarter. Vanguard Group Inc. now owns 76,242 shares of the biopharmaceutical company’s stock worth $623,000 after buying an additional 900 shares in the last quarter. FMR LLC bought a new stake in CoLucid Pharmaceuticals during the second quarter worth approximately $554,000. Finally, Societe Generale bought a new stake in CoLucid Pharmaceuticals during the second quarter worth approximately $464,000. Hedge funds and other institutional investors own 36.92% of the company’s stock.

About CoLucid Pharmaceuticals

CoLucid Pharmaceuticals, Inc is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies.

5 Day Chart for NASDAQ:CLCD

Receive News & Ratings for CoLucid Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CoLucid Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.